CA2323111A1 — New substituted indolinones, the preparation thereof and their use as pharmaceutical compositions
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 1999-10-21 · 27y expired
What this patent protects
The present invention relates to substituted indolinones of general formula (see formula I) wherein R1 to R5 and X are defined as in claim 1, the isomers thereof and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological p…
USPTO Abstract
The present invention relates to substituted indolinones of general formula (see formula I) wherein R1 to R5 and X are defined as in claim 1, the isomers thereof and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, particularly an inhibitory effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.